Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
Fuji Pharma has entered into an agreement with Luxemburg-based Alvotech Holdings to acquire a 4.2% stake in the biopharma for US$50 million. Earlier in November, the Japanese company closed an exclusive partnership deal with Alvotech Holdings’ Iceland subsidiary for the…
To read the full story
Related Article
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Fuji Pharma to File Biosimilars for Japan Approval by 2021: President
May 20, 2019
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…